Derisking xenobiotic-induced nongenotoxic carcinogenesis (NGC) represents a significant challenge during the safety assessment of chemicals and therapeutic drugs. The identification of robust mechanism-based NGC biomarkers has the potential to enhance cancer hazard identification. We previously demonstrated Constitutive Androstane Receptor (CAR) and WNT signaling-dependent up-regulation of the pluripotency associated Dlk1-Dio3 imprinted gene cluster noncoding RNAs (ncRNAs) in the liver of mice treated with tumor-promoting doses of phenobarbital (PB). Here, we have compared phenotypic, transcriptional ,and proteomic data from wild-type, CAR/PXR double knock-out and CAR/PXR double humanized mice treated with either PB or chlordane, and show that hepatic Dlk1-Dio3 locus long ncRNAs are upregulated in a CAR/PXR-dependent manner by two structurally distinct CAR activators. We further explored the specificity of Dlk1-Dio3 locus ncRNAs as hepatic NGC biomarkers in mice treated with additional compounds working through distinct NGC modes of action. We propose that up-regulation of Dlk1-Dio3 cluster ncRNAs can serve as an early biomarker for CAR activator-
Assessing the risk for xenobiotic-induced nongenotoxic carcinogenesis (NGC) is a major challenge for safety scientists. This is exemplified by the broad range of cancer hazard identification strategies that are selectively deployed during the preclinical development of novel therapeutics based on their modality, mode of action, disease indication, and phase of development (Moggs et al. 2016) . Derisking drug-induced carcinogenicity would benefit from the development of reliable mechanismbased biomarkers that enable early cancer hazard identification and also enhance mechanistic insight for positive tumor findings in life-time rodent carcinogenicity studies.
The liver is a major target organ for xenobiotic-induced NGC. We have used Phenobarbital (PB), an anticonvulsant commonly used for treatment of epilepsy and other seizures, as a model compound to study mechanisms underlying liver NGC mechanisms. PB indirectly activates CAR through molecular pathways that have been reported to include the inhibition of epidermal growth factor receptor signaling (Mutoh et al. 2013) . PBmediated liver tumor promotion in mice is dependent on CAR and b-catenin (Huang et al. 2005; Rignall et al. 2011; Yamamoto et al. 2004 ). Furthermore, b-catenin harbors activating mutations in most CAR-dependent mouse liver tumors (Unterberger et al. 2014; Aydinlik et al. 2001) . Through integrated molecular profiling, we previously uncovered an early, progressive and long-lasting, CAR-and b-catenin-dependent up-regulation of the Dlk1-Dio3 imprinted cluster ncRNAs in perivenous hepatocytes of mice treated with tumor-promoting doses of PB (Lempiainen et al. 2013; Luisier et al. 2014) . Several groups have reported a potential role for Dlk1-Dio3 derived noncoding transcripts in stem cell pluripotency (Liu et al. 2010; Stadtfeld and Hochedlinger 2010) . The overexpression of the human Dlk1-Dio3 miRNA cluster was also positively correlated with expression of hepatocellular carcinoma (HCC) stem cells markers and was also associated with poor survival rate in HCC patients (Luk et al. 2011) . Many of the Dlk1-Dio3 cluster miRNAs are differentially expressed in hepatocellular carcinomas (Benetatos et al. 2014; Cui et al. 2015; Xu et al. 2013; Yin et al. 2013) . Together, these observations highlight a pathophysiological role for Dlk1-Dio3 ncRNA dysregulation in liver cancer and support their functional relevance as early NGC biomarkers.
Xenobiotic-induced activation of CAR and/or Pregnane X receptor (PXR) triggers an immediate activation of specific subsets of cytochrome P450 (CYP)-encoding genes, including the Cyp2b and Cyp2c family isoforms. CAR and PXR transactivate a large battery of genes involved in phase I oxidation and phase II conjugation pathways that contribute to xenobiotic metabolism. PXR and CAR receptors have overlapping functions in the regulation of xenobiotic metabolism genes such as Cyp3a, whilst CAR-and PXR-specific target genes have also been identified (Cui and Klaassen 2016; Wei et al. 2002) . Chronic CAR activation by PB or other (in)direct activators is associated with hepatocellular carcinoma, liver injury, glucose metabolism, and cholesterol homeostasis (Kobayashi et al. 2015) . It was previously proposed that monitoring of P450-encoding genes such as Cyp2b10, one of the most strongly regulated CAR targets, could provide a robust surrogate biomarker of CAR activation in drug-induced mouse liver tumors (Hoflack et al. 2012) .
To explore further the NGC-specificity and CAR-activation dependence of xenobiotic-induced liver Dlk1-Dio3 long noncoding RNAs (lncRNAs) activation, we compared phenotypic, transcriptional, and proteomic data from wild-type and CAR/PXR transgenic C57BL/6 mouse models following in vivo treatment with PB and the pesticide-derived CAR-activator chlordane (Malarkey 1995; Moser and Smart 1989; Ruch et al. 1990 ). We further investigated selected transcriptional profiles from mouse liver samples exposed to additional NGC compounds that work through different modes of action (MoA), and show that up-regulation of hepatic Dlk1-Dio3 cluster noncoding RNAs represents a common feature of CAR-activating compounds. Our study highlights Dlk1-Dio3 imprinted cluster lncRNAs as potential CAR activator-specific hepatic biomarkers that warrant further evaluation as tools for mechanism-based safety assessment of xenobiotic-induced liver nongenotoxic carcinogenesis.
MATERIALS AND METHODS
Ethics statement. In vivo mouse studies were performed either according to the Institutional Guidelines of the University of Tü bingen (Rignall et al. 2011) (Ross et al. 2010; Barrass et al. 1993) . After 28 days (t ¼ 28) of treatment, the compound was withdrawn and the recovery group animals kept for a further 28 days for reversibility assessment (t ¼ 56). At sacrifice, on day 29 (2 h post-dose) and 57 (recovery period), blood was sampled for pharmacokinetics (PK) analysis and hepatic lobes were collected and either frozen in liquid nitrogen and stored at À80 C for subsequent analyses or fixed in neutral phosphate-buffered formalin and paraffin-embedded (FFPE ) mice chronically exposed for 28 days (t ¼ 28), 91 days (t ¼ 91) or 91 days followed by 28 days of recovery (t ¼ 119) from were analyzed. Additional justification on compounds dose selection is available in Supplementary Materials and Methods.
Cross-compound data mining, Affymetrix labeling, GeneChip processing and gene expression analysis. We performed data mining of in vivo gene expression profiles produced by the MARCAR consortium (http://www.imi-marcar.eu/; last accessed May 29, 2017) encompassing 6 well-known liver NGC compounds: Phenobarbital (PB), Pirinixic acid (Wy), Piperonyl Butoxide (PBO), 1,4-dichlorobenzene (DCB), Cyproterone acetate (CPA), and methapyrilene (Mpy). Pioglitazone (Pio) was used as a nonhepatocarcinogen compound and CITCO as a human specific CAR activator. Data sets of Wy, PBO, DCB, CPA, MPY, PB, CITCO, and Pio studies were publically released and available at NCBI's GEO (GSE68364 and GSE60684). Affymetrix labeling and GeneChip (Mouse Genome 430 2.0 Array) processing were conducted as described in Lempiainen et al. (2013) . Heatmaps were built using TIBCO SpotfireV R . GeneChip and qPCR expression data analyses were described in Supplementary Materials and Methods.
RT-qPCR analyses. RNA isolation and quantitative RT-PCR analyses were performed as previously described Lempiainen et al. (2013) and are detailed in Supplementary Materials and Methods. All expression analyses are based on qPCR, primer sequences are provided in Lempiainen et al. (2013) and Supplementary Materials and Methods. Data were analyzed using GraphPad Prism 7.0. Statistical significance of treated versus untreated (vehicle) qPCR signal differences (n ¼ 5/group) were tested using unpaired t-tests with Welch's correction for unequal variance.
Proteomic analysis. Sample preparation, data acquisition and analysis by targeted high resolution single ion monitoring (tHR/ SIM) in vivo "stable isotope labeling by amino acids in cell culture" (SILAC) using a pathway-enhanced internal standard was carried out as described previously (MacLeod et al. 2015) (Supplementary Material and Methods). For generation of the hierarchical clustering heatmaps, Xcalibur files were processed using MaxQuant, version 1.4.1.2, (Cox and Mann 2008) and the integrated Andromeda search engine with the Uniprot Mus musculus (taxID: 10090) reference proteome set (44,455 entries, downloaded 03.12.14). Cysteine carbamidomethylation was set as a fixed modification, with N-terminal acetylation and methionine oxidation as variable modifications. The protein false discovery rate was set to 1%, minimum peptide length was 7 and a maximum of 2 miscleavages was allowed. Data were processed in Perseus (version 1.5.1.6). For each control/xenobiotic comparison, only proteins with !3 valid values were retained. Data were analyzed using GraphPad Prism 7.0. Statistical significance of treated versus untreated (vehicle) signal differences were tested using multiple unpaired t-tests on log2 transformed data. The P values were adjusted using HolmSidak method, with alpha ¼ 0.05.
For proteomics heatmap generation, individual animal data were normalised to the mean of the control group, log 2 -transformed and missing values imputed from normal distribution. Clustering was generated in R using the RStudio interface with the gplots and RColorBrewer packages.
In situ hybridization (ISH) and immunohistochemistry (IHC). Meg3 in situ hybridization (ISH) and glutamine synthetase (GS) immunohistochemistry (IHC) were conducted on liver samples of chlordane-and PB-treated animals as previously described (Lempiainen et al. 2013) , detailed in Supplementary Materials and Methods.
RESULTS

Comparable Liver Phenotypic and Histopathologic Responses
Following 28 Days In Vivo PB and Chlordane Treatment of Mice We previously showed that the Dlk1-Dio3 transcriptional response mediated by PB is CAR-dependent (Lempiainen et al. 2013; Luisier et al. 2014) . In order to further evaluate the specificity of this candidate NGC biomarker for CAR activators, we compared the effects of PB and chlordane in the liver of WT, CAR/PXR double knockout (CAR K -PXR K ) and double human-
) C57BL/6 animals after 28 days (t ¼ 28) treatment with either compound ( Figure 1A ). Akin to PB, chlordane is a NGC compound which induces hepatomegaly characterized by hypertrophy and hyperplasia and acts through robust CAR activation (Ross et al. 2010; Barrass et al. 1993; Malarkey 1995; Whysner et al. 1998) .
No significant body weight differences were observed comparing 28 days PB and chlordane treated samples (Table 1) . Microscopically, similar histopathological changes were observed in liver, characterized by moderate centrilobular hepatocellular hypertrophy in WT after 28 days with both treatments. Centrilobular hepatocytes showed cytoplasmic changes with an eosinophilic and/or granular basophilic cytoplasm in chlordane treated samples (data not shown). Comparable, moderate to marked, changes were also made in CAR Interestingly, plasma concentration of chlordane-treated samples showed appreciable compound levels after 28 days of recovery (t ¼ 56, 1 lg/ml in WT animals) consistent with chlordane's long half-life (Zucker 1985) . PB on the other hand was undetectable after 28 days recovery (t ¼ 56) (Table 1) . Overall, the liver histopathological changes induced by chlordane are CAR/PXR-activation dependent and similar to those induced by PB.
Both Chlordane and PB Induce Dlk1-Dio3 lncRNAs Up-Regulation in Perivenous Hepatocytes
We next investigated the transcriptional response of Dlk1-Dio3 lncRNAs in chlordane and PB treated mice. Using RT-qPCR, we profiled the expression of both coding and long noncoding transcripts throughout the Dlk1-Dio3 cluster in 28-day PB and chlordane liver study samples (t ¼ 28) ( Figure 1A ). The imprinted Dlk1-Dio3 locus contains 3 protein coding genes (Dlk1, Dio3, and Rtl1) expressed from the paternally inherited allele, and several maternal-of-origin lncRNAs (Meg3, antiRtl1, Rian, and Mirg) (Benetatos et al. 2014 ) ( Figure 1B ). Strikingly, PB and chlordane triggered comparable transcriptional activation of Meg3, antiRtl1, Rian, and Mirg lncRNAs in wild-type animals ( Figure 1C ) with no detectable activation of the coding genes Dlk1 and Dio3. Consistent with long half-life of chlordane (Table 1) , increased levels of Meg3, antiRtl1, Mirg, and Cyp2b10 expression were observed in chlordane (but not PB) recovery group animals (t ¼ 56 and t ¼ 119, respectively) (Supplementary Figure 1) .
We had previously shown that Meg3 expression occurs within a specific subset of perivenous hepatocytes expressing glutamine synthetase (GS) following PB treatment (Lempiainen et al. 2013 ). The Glul gene encoding for the GS protein is a target regulated positively by the WNT signaling pathway and is also expressed in PB-promoted tumors (Loeppen et al. 2002) . Immunohistochemistry (IHC) and in situ hybridization (ISH) Figure 1 . Dlk1-Dio3 cluster response upon 28 days phenobarbital or chlordane exposure. A, Experimental design of the chlordane and PB studies for molecular and phenotypic profiling. B, Architecture of Dlk1-Dio3 genomic region illustrating parent-of-origin transcripts and differentially methylated regions (DMR)-methylated regions are represented with solid circles. C, RT-qPCR analysis of Dlk1-Dio3 genes (Dlk1 and Dio3) and long noncoding RNAs (Meg3, antiRtl1, Rian, and Mirg) expression in wild type (WT) mouse livers treated for 28 days with PB, chlordane or the relevant vehicle controls. Expression levels are indicated as mean 6 SEM (n ¼ 5 biological replicates/group). Data were analyzed using GraphPad Prism 7.0. Statistical significance of treated versus untreated (vehicle) qPCR signal differences were tested using unpaired t-tests with Welch's correction for unequal variance, *P < 0.05, **P < 0.01. D, Meg3 in situ hybridization and GS immunohistochemistry in 28 days PB or in chlordane treated livers with indicated vehicle controls. Water (H2O), Corn Oil (CO).
directed against GS and Meg3, respectively, showed similar Meg3 lncRNA distribution and no apparent change in GS expression levels with either compound in 28-day treated samples (Figure 1D ), altogether consistent with CAR-and b-catenin dependence of the Dlk1-Dio3 lncRNAs activation. ) mouse models were used to examine CAR/PXR dependencies and potential species differences in receptor-dependent responses to chlordane ( Figure 1A ). As described previously , PB led to comparable activation of Dlk1-Dio3 lncRNAs in WT and humanized mice models ($20-fold increase over vehicle controlscompare Figs. 2A and 1C, red bars) . In contrast, while chlordane treatment led to over 10-fold induction of Dlk1-Dio3 lncRNAs in WT animals ( Figure 1C , orange bars), the cluster was minimally induced ($2.5-fold induction over control) upon chlordane treatment of CAR h -PXR h animals ( Figure 2A ). Consistently, lower levels of Cyp2b10 ( Figure 2C ) were also detected in chlordane-treated CAR h -PXR h mice expressing hCAR ( Figure 2D )
as compared with WT animals. KO animal models showed no Meg3 expression ( Figure 2B ) and no detectable Cyp2b10 ( Figure  2C ) activation upon chlordane treatment, consistent with the previously reported CAR dependence of PB effects . The differential transcriptional responses observed for PB versus chlordane in humanized CAR/PXR mice might be related to distinct, possibly species-specific, mechanisms of CAR activation by chlordane.
Proteome-Based Analyses of Xenobiotic Metabolism Pathways in WT and CAR h -PXR h Mouse Liver Following PB and Chlordane Exposure
To further investigate the transcriptomic differences observed in CAR h -PXR h animals upon chlordane and PB treatments, we next performed peptide quantification using stable isotope labeling by amino acids in cell culture (SILAC) analysis of a wide range of enzymes implicated in xenobiotic metabolism using liver tissues from WT and humanized animals treated for 28 days with PB or chlordane. In WT animal samples, we found a comparable pattern of phase I cytochrome P450 protein expression following chlordane and PB treatments (Figure 3 ). Cyp2b10, one of the strongest activated protein targets, showed significantly increased protein expression levels following both chlordane and PB treatment (Figure 3 ). Selected proteins were strongly induced by PB but not by chlordane (eg, Cyp2c54 and Cyp2c55), or inversely were more strongly induced by chlordane than PB (eg, Por, Ces2a, Gstm3, and Gstt3), in WT animals ( Figure 3 and Supplementary Figs. 3 and 4) . Together these data suggest that the repertoire of xenobiotic genes activated by both compounds is largely but not fully overlapping. It is noteworthy that we also found consistent transcriptional and protein level induction in PB-treated WT mice (Supplementary Figure 2) . Consistent with the lower Cyp2b10 transcriptional expression in CAR h -PXR h animals ( Figure 2C ), we observed reduced levels of a number of measured peptides corresponding to Cyp2b10/2b23, Cyp2c55, and Por enzymes in chlordane-treated humanized animals (Figure 3, arrowed standard deviation. In vivo data referring to the phenobarbital study are adapted from . Centrilobular hypertrophy severity grades were on a 0-4 scale, expressed as median (n ¼ 5).
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CAR Activator Specificity of Dlk1-Dio3 lncRNAs Upregulation in Mouse Liver
We next evaluated microarray-based liver transcriptomic profiles derived from mice treated with a panel of structurally distinct rodent nongenotoxic carcinogens that work through distinct modes of action (studies were conducted Innovative Medicines Initiative MARCAR consortium http://www.imi-mar car.eu/ (last accessed May 29, 2017); original gene expression profiling data available in Gene Expression Omnibus (GEO) under GSE68364 and GSE60684). For enhanced comparability, among all studies available, we selected data based on (1) study duration, selecting for studies of 28 days and above duration, at a stage when Dlk1-Dio3 lncRNAs have been detected unambiguously upon PB treatment in B6C3F1 or C57BL/6 mice (Lempiainen et al. 2013; Luisier et al. 2014 ) and (2) study strain, C57BL/6 studies were chosen to limit the interstrain variability of the response. All available compound studies fulfilling these conditions were selected and included one cross-species CAR activator (PB), one human-specific CAR activator (CITCO) and 5 rodent . Expression levels are indicated as mean 6 SEM (n ¼ 5 biological replicates/group). Data were analyzed using GraphPad Prism 7.0. All expression analyses are based on qPCR, primer sequences are provided in (Lempiainen et al. 2013) and Supplementary Materials and Methods. Statistical significance of treated versus untreated (vehicle) qPCR signal differences were tested using unpaired t-tests with Welch's correction for unequal variance, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Vehicle controls: Water (H 2 O) and Corn Oil (CO). models or on experiments conducted on PB treated hepatocytes-detailed in Supplementary Table 2 and references within). While we detected the expected CAR-dependent activation of the selected xenobiotic response genes upon PB treatment, we also observed activation of Cyb2b10 and other selected xenobiotic metabolism genes upon treatment with a range of distinct hepatic NGCs (Figure 4) . Specifically, Cyp2b10 expression was strongly regulated by CPA and DCB, and also by Pioglitazone (Pio), a PPARc agonist that we included as a negative control for liver NGC (Log 2 FC from 6.99 to 7.67 for the 3 compounds, P < 0.001, Supplementary Table 3 ). These data indicate that multiple signaling pathways can converge to mediate Cyp gene regulation. The CAR dependency of induction of Cyp2b and Cyp2c gene expression upon PB treatment was confirmed in CAR K -PXR K mice, as previously reported (Kobayashi et al. 2015 ).
Among the 6 rodent hepatic NGCs tested in this experiment, only PB treated liver samples showed increased Meg3 and Rian expression (Meg3 Log 2 FC close to 2 in wild-type and humanized models upon 28 and 91 days of PB treatment, absent in CAR K -PXR K animals) (Figure 4) . None of the other 5 hepatic NGCs led to a significant induction of Meg3 or Rian regardless of the mouse strains or durations of exposure that were tested. CITCO, a direct and human-specific CAR agonist (Yang and Wang 2014) Chlordane n ¼ 3 biological replicates/group). Data were analyzed using GraphPad Prism 7.0. Statistical significance of treated versus untreated (vehicle) signal differences were tested using multiple unpaired t-tests on log2 transformed data. The P values were adjusted using Holm-Sidak method, *P < 0.05, **P < 0.01, ***P < 0.001.
Vehicle controls: Water (H2O) and Corn Oil (CO).
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DISCUSSION
Nongenotoxic carcinogenesis is a key safety assessment consideration for the development of chemicals and therapeutic drugs. There are currently no suitable short-term assays for predicting NGC. The identification of mechanism-based NGC biomarkers would provide industry and regulatory scientists with new tools and opportunities for earlier decision-making, mitigation of positive carcinogenicity findings and enhanced cancer risk assessment. There are, however, a number of significant challenges associated with the identification and application of NGC biomarkers (Moggs et al. 2016) . Firstly, multiple combinations and chronologies of cancer hallmarks contribute to tumorigenicity and thus the detection of individual drug-induced neoplastic risk molecular indicators is not likely to be optimal for predicting diverse mechanisms of xenobiotic-induced carcinogenesis. Secondly, the identification of predictive transcriptomic NGC biomarkers in rodent carcinogenicity studies is confounded by the heterogeneity of drug-induced rodent tumors that cover a broad range of tissue-, gender-, strain-, and species-specific mechanisms. Furthermore, the potential contributions from on-or off-target properties of NGC compounds makes the determination of mode of action and assessment of human relevance very challenging. Nevertheless, mechanistic studies that integrate phenotypically anchored molecular and biochemical biomarkers can be used to support the interpretation of druginduced tumors and in some cases provide valuable perspectives on potential relevance in humans. Although numerous publications report extensive efforts to identify predictive transcriptomic biomarkers for NGC, this has proved challenging even for a single target organ such as the liver (Kossler et al. 2015; Ellinger-Ziegelbauer et al. 2011; Fielden et al. 2011) . We propose that the validation of such molecular biomarkers will be greatly enhanced by establishing functional relationships to known cancer hallmarks. This is exemplified by the identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for phenobarbital-induced liver tumor promotion (Lempiainen et al. 2013) . The induction of Dlk1-Dio3 noncoding RNAs by phenobarbital is dependent on both constitutive androstane receptor (CAR) and b-catenin signaling pathways, consistent with a CAR activator-mediated hepatocarcinogenesis mode of action. Importantly, Dlk1-Dio3 non-coding RNAs have recently been associated with stem cell pluripotency in mice and various neoplasms in humans. In addition, the perivenous localization of phenobarbital-induced Dlk1-Dio3 noncoding RNAs occurs in a region of the liver that was recently associated with Wnt signaling-dependent stem cell-like properties (Wang et al. 2015; Planas-Paz et al. 2016) . Together, these functional relationships imply that subpopulation of hepatocytes may be prone to drug-induced reprogramming and dedifferentiation and that biomarkers such as Dlk1-Dio3 noncoding RNAs might serve as useful early molecular indicators for CAR-mediated hepatocarcinogenesis (Supplementary Figure 5) . Specifically, in this paper, we have compared phenotypic, histopathological, transcriptional and proteomic responses following treatment with the cross-species CAR activators, PB and chlordane, and further compared key transcriptional signatures with 7 other NGC compounds working through a range of MoAs (Supplementary Table 1 ), including the human-specific direct CAR activator CITCO. We find that the xenobiotic metabolism gene Cyp2b10 is upregulated by several distinct hepatic NGCs as well as the PPARc agonist Pioglitazone (a control comparator compound that is not associated with hepatic NGC). Although Cyp2b10 induction in drug-induced mouse liver tumors has previously been proposed as a surrogate biomarker of CAR activation (Hoflack et al. 2012) , our data suggest that Cyp2b10 induction alone may lack the required specificity for an early mechanism-based biomarker of CAR-mediated NGC consistent with previous observations that induction of CYP2B1/2 liver enzymes failed to correlate with rodent NGC (Elcombe et al. 2002) . In contrast, our data provide additional support to the CAR activator specificity of previously identified Dlk1-Dio3 lncRNA candidate biomarkers for mouse liver tumor promotion (Lempiainen et al. 2013 ).
Since we used double transgenic (CAR K -PXR K and CAR h -PXR h ) animals in the PB and chlordane in vivo studies, we cannot formally exclude the role of PXR activation and function in the identified molecular signature. CAR shares several common features with PXR, and they overlap at a number of target genes and xenobiotic activators (Yang and Wang 2014) . Although previous studies in CAR and PXR KO models also identified differentially regulated xenobiotic targets (Maglich et al. 2002; Wei et al. 2002; Cui and Klaassen 2016) , the strict specificity to CAR versus PXR may require further investigations.
While both cross-species CAR activators, PB and chlordane, led to Dlk1-Dio3 lncRNAs activation, consistent with its direct human CAR activation MoA (Maglich et al. 2003) , CITCO did not lead to either xenobiotic genes or Dlk1-Dio3 cluster lncRNAs activation in WT animals ( Figure 4 ) and led to moderate Cyp2b10 activation, without effect on Dlk1-Dio3 lncRNAs in CAR/PXR humanized animals. The absence of lncRNAs activation by CITCO is reminiscent of the significantly decreased lncRNAs activation upon chlordane exposure in humanized animals and could be related to species-specific interactions upstream or downstream of CAR/PXR activation that could be perturbed in the human transgenic model ( Figure 5 ). In addition, CITCO acts through direct CAR binding and activation, and a conformational change of the hCAR isoforms in transgenic animals might also explain the apparent differences in Cyp induction and lack of Dlk1-Dio3 cluster activation. Alternatively, the exposure or duration of the study in the transgenic animal studies may not be sufficient to detect Dlk1-Dio3 lncRNAs activation. Finally, we Lempiainen et al. [2013] ). Direct CAR activators or indirect compounds acting through cellular transducers (green triangle, eg, as described in Mutoh et al. [2013] ) regulate the expression of CAR-dependent xenobiotic genes. The b-catenin pathway regulates expression of xenobiotic metabolic genes in a context dependent manner (Braeuning et al. 2009 ). Within WNT positive domains (eg, perivenous hepatocytes) CAR activation is also associated with Dlk1-Dio3 cluster ncRNAs expression. The current model acknowledges the presence of intermediate/uncharacterized co-effectors (orange hexagons) acting downstream CAR activation, and possibly linking the constitutive xenobiotic metabolism and the progressive CAR/b-catenin dependent response. The upregulation of Dlk1-Dio3 cluster ncRNAs might contribute to hepatocyte hypertrophy and reprogramming (Luk et al. 2011) , while xenobiotic response may lead to oxidative stress through the production of reactive metabolites (Omura et al. 2014) , both contributing potential key events in drug-induced tumor promotion. POUCH E ET AL. | 375 note that only 2 long noncoding RNAs (Meg3 and Rian) are represented on the microarray used to profile compounds in Figure 4 and thus we cannot exclude that CITCO induces alternate Dlk1-Dio3 ncRNAs. Further analyses of the complete Dlk1-Dio3 cluster transcriptional landscape following longer-term CITCO treatment in PXR h -CAR h animals would be necessary to extend these observations as well as to explore the relevance of this compound in liver carcinogenesis. Three of the compounds tested (CPA, DCB, and Pio), in addition to PB and CITCO, led to significant activation of Cyp2b10 and Cyp2c55. However, under the experimental conditions tested, they did not induce detectable microarray-based dysregulation of Dlk1-Dio3 cluster lncRNAs Meg3 or Rian. Interestingly, using CYP2B6LacZ reporter and CAR/PXR humanized mouse models, both DCB and CPA were recently characterized as CAR activators with DCB displaying a higher potency towards human CAR than mouse CAR, and CPA activating both CAR and PXR (CJH, CRW, unpublished, manuscript in preparation). While no microarray-based upregulation of the Dlk1-Dio3 lncRNAs Meg3 and Rian was detected for either DCB or CPA, quantitative PCR-based expression data indicated upregulation of several noncoding miRNAs within the Dlk1-Dio3 cluster for both of these compounds (unpublished MARCAR data), consistent with our proposal that CARactivation leads to Dlk1-Dio3 cluster ncRNAs perturbations in liver NGC models. It is noteworthy that the Dlk1-Dio3 cluster encodes one of the largest microRNA clusters in the mammalian genome, as well as numerous small nucleolar RNAs (snoRNAs). We previously demonstrated PB-mediated induction both lncRNAs and miRNAs from the Dlk1-Dio3 locus (Lempiainen et al. 2013) . Interestingly, some Dlk1-Dio3 cluster miRNAs appear to be transcribed as single polycistronic unit (Fiore et al. 2009 ) and many of these miRNAs have been reported to be differentially expressed in pathologic processes including various cancers (reviewed in Benetatos et al. 2013) . In this manuscript, we have evaluated the hepatic responsiveness of 4 Dlk1-Dio3 cluster long-noncoding RNAs (Meg3, antiRtl1, Rian, and Mirg) by qPCR (PB and chlordane), and of 2 Dlk1-Dio3 cluster long-noncoding RNA (Meg3 and Rian) by microarray-based transcript profiling (panel of compounds in Figure 4 ). We cannot exclude that the compounds tested induce further broad or specific changes of the Dlk1-Dio3 noncoding RNAs landscape and thus further RNA-sequencing based assessments of Dlk1-Dio3 ncRNAs candidate biomarkers is warranted. Beyond their association with pluripotency (Liu et al. 2010; Stadtfeld and Hochedlinger 2010) , the interest in investigating the expression profile on the Dlk1-Dio3 cluster lncRNAs, has been reinforced by the discovery that they are able to form complexes with the epigenetic machinery, including Polycomb group proteins (Kaneko et al. 2014 ) and might be targeted to specific genes through the formation of RNA-DNA triplex structures (Mondal et al. 2015) . These regulatory interactions (illustrated Supplementary Figure  5 ) could play an important role in cellular transformation.
CONCLUSIONS
In the present study we have demonstrated that a second CAR activator and mouse liver nongenotoxic carcinogen (ie, chlordane) robustly induces perivenous Dlk1-Dio3 noncoding RNAs expression and we provide preliminary evidence that this candidate biomarker signature may indeed be specific for CARmediated hepatocarcinogenesis. Through comparing the response to chlordane and PB exposure in WT and humanized animals, we also point to the existence of undetermined coeffector phenomenon, upstream or downstream to CAR activation ( Figure 5 ). Since significant molecular, cellular and pathophysiologic differences exist between mammalian species and strains, further evaluation of Dlk1-Dio3 cluster noncoding RNAs functions, biomarker detection sensitivity, MoA specificity and human relevance, is warranted prior to use as an early indicator for CAR-mediated hepatocarcinogenesis. In particular, mapping species differences in the hepatic chromatin architecture of candidate nongenotoxic carcinogen effector genes such as Dlk1-Dio3 ncRNAs may help predict the potential for NGCmediated modulation in humans (A.V., R.T., and J.M., unpublished data).
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